Heparin in malignant glioma: review of preclinical studies and clinical resultsReport as inadecuate




Heparin in malignant glioma: review of preclinical studies and clinical results - Download this document for free, or read online. Document in PDF available to download.

Journal of Neuro-Oncology

, Volume 124, Issue 2, pp 151–156

First Online: 30 June 2015Received: 10 January 2015Accepted: 24 May 2015DOI: 10.1007-s11060-015-1826-x

Cite this article as: Schnoor, R., Maas, S.L.N. & Broekman, M.L.D. J Neurooncol 2015 124: 151. doi:10.1007-s11060-015-1826-x

Abstract

Glioblastoma multiforme GBM is the most common primary brain tumor that is invariably lethal. Novel treatments are desperately needed. In various cancers, heparin and its low molecular weight derivatives LMWHs, commonly used for the prevention and treatment of thrombosis, have shown therapeutic potential. Here we systematically review preclinical and clinical studies of heparin and LMWHs as anti-tumor agents in GBM. Even though the number of studies is limited, there is suggestive evidence that heparin may have various effects on GBM. These effects include the inhibition of tumor growth and angiogenesis in vitro and in vivo, and the blocking of uptake of extracellular vesicles. However, heparin can also block the uptake of potential anti-tumor agents. Clinical studies suggest a non-significant trend of prolonged survival of LMWH treated GBM patients, with some evidence of increased major bleedings. Heparin mimetics lacking anticoagulant effect are therefore a potential alternative to heparin-LMWH and are discussed as well.

KeywordsGlioblastoma multiforme Glioma Heparin Low molecular weight heparin Electronic supplementary materialThe online version of this article doi:10.1007-s11060-015-1826-x contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Rosalie Schnoor - Sybren L. N. Maas - Marike L. D. Broekman

Source: https://link.springer.com/







Related documents